Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a tailored palliative care approach improve life for heart failure patients?

NCT ID NCT06244953

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests a new care model called TIER-HF-PC, which matches heart failure patients to one of three levels of palliative support based on their needs. Researchers want to see if this approach improves quality of life for both patients and their caregivers compared to usual care. The trial involves 240 participants with advanced heart failure and follows them for up to 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a tiered palliative care model (TIER-HF-PC) that assigns patients to different levels of care based on their needs
What this could lead to
If successful, this could provide a practical, scalable way to integrate palliative care into heart failure management, improving quality of life for patients and easing the burden on caregivers.
What could go wrong
This is a relatively small study testing a complex care model, so results may not apply broadly. The intervention involves multiple components, making it hard to pinpoint which part works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients: 1. 21 years or older and 2. able to communicate in English/Chinese/Malay and 3. be of stage C or D heart failure, as defined by American College of Cardiology/American Heart Association (ACC/AHA) classification system and 4. have functional limitation of New York Heart Association (NYHA) functional status of at least 2 or more and 5. be deemed by their cardiologist's clinical judgement to have an expected prognosis of at least 6 months survival, and 6. have had a heart failure related hospitalization event (e.g. symptomatic decompensated heart failure) within 6 months prior to recruitment and 7. have a phone that allows telecommunication. * Caregivers must meet all the following inclusion criteria to be eligible for the study : * direct, unpaid, family caregiver of the patient; * self-reported by the patient to be the main person to be either: * responsible for up to 4 hours a day of caregiving tasks * and/or decision maker/spokesperson with the medical team * Caregiver may or may not live in the same residence as the patient. * Caregivers must be 21 years and above. * Able to communicate in English/Chinese/Malay. Exclusion Criteria: * Patients: 1. have cognitive impairment (e.g., dementia) 2. have severe, untreated, active mental illness (e.g., major depressive disorder) 3. have ventricular assist device implant. 4. have non-reversible hearing or visual loss or 5. are active drug abuser or 6. already known to a palliative care service. * Caregivers who meet any of the exclusion criteria at baseline will be ineligible for the study: * have cognitive impairment (e.g., dementia) or * have severe, untreated, active mental illness (e.g., major depressive disorder) * have non-reversible hearing or visual loss. * are active drug abuser or * are a domestic helper for the patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Khoo Teck Puat Hospital

    RECRUITING

    Singapore, 768828, Singapore

  • National Cancer Centre, Singapore

    RECRUITING

    Singapore, Singapore

  • National Heart Centre Singapore

    RECRUITING

    Singapore, 169609, Singapore

  • Sengkang General Hospital

    RECRUITING

    Singapore, 544886, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.